Induction of transmission-blocking immunity in aotus monkeys by vaccination with a Plasmodium vivax clinical grade Pvs25 recombinant protein

被引:17
作者
Arévalo-Herrera, M
Solarte, Y
Yasnot, MF
Castellanos, A
Rincón, A
Saul, A
Mu, JB
Long, C
Miller, L
Herrera, S
机构
[1] Malaria Vaccine & Drug Dev Ctr, Cali 26020, Colombia
[2] Univ Valle, Inst Inmunol Valle, Cali, Colombia
[3] NIAID, Malaria Vaccine Dev Branch, NIH, Bethesda, MD 20892 USA
[4] NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.4269/ajtmh.2005.73.32
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Aotus monkeys were used to determine the immunogenicity of Pvs25 protein expressed in the zygote/ookinete surface. Animals were immunized in three times with 100 mu g of Pvs25 formulated in Montanide ISA-720. Antibodies to Pvs25 detected by an enzyme-linked immunosorbent assay appeared by day 30 after the first immunization, with a peak of antibodies levels on day 150. These antibodies were still detectable on day 300. Plasma samples on day 150 from experimental group were able to completely block the development of the parasite in Anopheles albimanus mosquitoes artificially fed with human isolates of Plasmodium vivax. Immunized Aotus monkeys were infected with blood forms of the P. vivax Salvador I strain and no boosting effect of blood infection on titers of antibodies to Pvs25 was observed despite the presence of infective gametocytes. In conclusion, Pvs25 protein formulated in Montanide ISA-720 induces efficient and long-lasting transmission-blocking antibodies that cannot be boosted by parasite infection.
引用
收藏
页码:32 / 37
页数:6
相关论文
共 26 条
[1]   Serum antibodies induced by intranasal immunization of mice with Plasmodium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes [J].
Arakawa, T ;
Tsuboi, T ;
Kishimoto, A ;
Sattabongkot, J ;
Suwanabun, N ;
Rungruang, T ;
Matsumoto, Y ;
Tsuji, N ;
Hisaeda, H ;
Stowers, A ;
Shimabukuro, I ;
Sato, Y ;
Torii, M .
VACCINE, 2003, 21 (23) :3143-3148
[2]   RECOMBINANT PFS25 PROTEIN OF PLASMODIUM-FALCIPARUM ELICITS MALARIA TRANSMISSION-BLOCKING IMMUNITY IN EXPERIMENTAL-ANIMALS [J].
BARR, PJ ;
GREEN, KM ;
GIBSON, HL ;
BATHURST, IC ;
QUAKYI, IA ;
KASLOW, DC .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (05) :1203-1208
[3]   TREATMENT OF VIVAX MALARIA WITH SULFADOXINE-PYRIMETHAMINE AND WITH PYRIMETHAMINE ALONE [J].
DOBERSTYN, EB ;
TEERAKIARTKAMJORN, C ;
ANDRE, RG ;
PHINTUYOTHIN, P ;
NOEYPATIMANONDH, S .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1979, 73 (01) :15-17
[4]  
Filler Scott, 2003, MMWR Surveill Summ, V52, P1
[5]  
Friedman D, 2001, HARVARD J LAW PUBL P, V25, P71
[6]   Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea [J].
Genton, B ;
Al-Yaman, F ;
Anders, R ;
Saul, A ;
Brown, G ;
Pye, D ;
Irving, DO ;
Briggs, WRS ;
Mai, A ;
Ginny, M ;
Adiguma, T ;
Rare, L ;
Giddy, A ;
Reber-Liske, R ;
Stuerchler, D ;
Alpers, MP .
VACCINE, 2000, 18 (23) :2504-2511
[7]   Saccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice [J].
Gozar, MMG ;
Price, VL ;
Kaslow, DC .
INFECTION AND IMMUNITY, 1998, 66 (01) :59-64
[8]   Antibodies to Plasmodium vivax transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 do not show synergism [J].
Hisaeda, H ;
Collins, WE ;
Saul, A ;
Stowers, AW .
VACCINE, 2001, 20 (5-6) :763-770
[9]   Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes [J].
Hisaeda, H ;
Stowers, AW ;
Tsuboi, T ;
Collins, WE ;
Sattabongkot, JS ;
Suwanabun, N ;
Torii, M ;
Kaslow, DC .
INFECTION AND IMMUNITY, 2000, 68 (12) :6618-6623
[10]   Regular production of infective sporozoites of Plasmodium falciparum and P-vivax in laboratory-bred Anopheles albimanus [J].
Hurtado, S ;
Salas, ML ;
Romero, JF ;
Zapata, JC ;
Ortiz, H ;
ArevaloHerrera, M ;
Herrera, S .
ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY, 1997, 91 (01) :49-60